News

   

Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO Immuno-Oncology Congress 2023

Updated safety and clinical efficacy data presented at leading…

Versameb AG Names Dr. Alexandre LeBeaut as Chair of the Board of Directors

Versameb AG (“Versameb”), a pre-clinical stage company focused…

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer

Experienced, innovative biotech and pharma leader with demonstrated…

The first six companies enter the Deep Tech Lab – Quantum start-up accelerator at BII to unlock the potential in quantum science

BioInnovation Institute (BII), an international non-profit foundation…

Poolbeg Pharma plc – Directorate Change

30 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…

Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus

Paris, France, 28 November, 2023 – Astraveus SAS (“Astraveus”…

Poolbeg Pharma – Immunomodulator II patent granted in Japan

21 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…

Biocomposites expands its product portfolio with the launch of SYNICEM™ spacers in the UK

SYNICEM™ hip, knee and shoulder spacers are preformed…

Poolbeg Pharma – POLB 001 LPS Challenge Trial Data to be Presented at IUIS

POLB 001 - a potential blockbuster immunomodulator 16 November…

Versameb Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence

Versameb AG (“Versameb”), a pre-clinical stage company focused…

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

Oxolife Appoints International Fertility Experts to its Scientific Advisory Board

Leading experts in fertility and human reproduction with…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.